Overview
Community and Healthcare Associated C. difficile: Prevention and Management of Recurrent Disease
Complimentary Breakfast Symposium Preceding IDWeek 2019.
Registration is closed for this activity.
This symposium will offer a lively discussion around two C. difficile patient interviews relating to community and healthcare associated CDI. Patients’ risks for initial and recurrent episodes, the impact of C. difficile on quality of life, and considerations in the selection of antimicrobial therapy will be addressed. The panel will also provide insights on improving outcomes and the patient experience.
This activity is intended for ID specialists, gastroenterologists, hospitalists, and other physicians, pharmacists and nurse practitioners who care for patients at risk of serious infection.
Clostridium difficile infection (CDI) is associated with significant morbidity, mortality, and impact on patient quality of life. Further, recurrence of CDI is common after an initial episode. Although several therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of recurrent and refractory CDI is complex and challenging. Clinicians require up-to-date knowledge of available guidelines and evidence-based treatment of recurrent CDI to reduce its burden and improve clinical outcomes.
Upon completion of this activity, participants will be able to:
• Implement tools to identify patients who may be at increased risk for recurrent C. difficile infection
• Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations
• Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection
• Implement tools to identify patients who may be at increased risk for recurrent C. difficile infection
• Outline evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations
• Describe the role of available antimicrobial agents and biologics for treatment and prevention of recurrent C. difficile infection
Marriott Marquis
901 Massachusetts Ave NW
Independence Ballroom ABCD (Meeting Level 4)
Washington, DC 20001 USA
Click here to view location map
901 Massachusetts Ave NW
Independence Ballroom ABCD (Meeting Level 4)
Washington, DC 20001 USA
Click here to view location map
7:30 am | Patient Case Presentation: Lorraine |
7:40 am | Epidemiology of C. difficile: What Places Patients At-risk? |
8:00 am | Guidelines and Approaches to Reduce Risk in Patients with C. difficile |
8:15 am | Patient Case Presentation: Melissa |
8:25 am | Prevention of Recurrent C. difficile |
8:45 am | Panel Discussion; Q&A |
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Company.
Erik Dubberke, MD, MSPH
Professor of Medicine
Clinical Director, Transplant Infectious Diseases
Washington University School of Medicine
St. Louis, MO
Professor of Medicine
Clinical Director, Transplant Infectious Diseases
Washington University School of Medicine
St. Louis, MO
Kevin Garey, PharmD, MS, FASHP
Chair, Department of Pharmacy Practice and Translational Research
Professor of Pharmacy Practice
University of Houston College of Pharmacy
Houston, TX
Jessica R. Allegretti, MD, MPH
Crohn's and Colitis Center
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA
Featuring video commentary from two CDI patients, Lorraine and Melissa
To receive credit, participants are required to participate in the live activity, complete the posttest and evaluation, and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate.
Partial credit may not be awarded for CPE credit (for pharmacists); participation in the complete activity is required to receive credit. CPE credit will be submitted to CPE Monitor® on the first day of each month.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.5 contact hours.
ACPE Universal Activity Number: 0396-0000-19-054-L01-P
Activity Type: Knowledge